Do, D., Murugiah, K., Sawano, M., Goodwin Cartwright, B. M., Rodriguez, P. J., Gratzl, S., … Stucky, N. L. (2026). FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity. JACC Adv, 5(2), 102575. https://doi.org/10.1016/j.jacadv.2025.102575

Do, Duy, Karthik Murugiah, Mitsuaki Sawano, Brianna M. Goodwin Cartwright, Patricia J. Rodriguez, Samuel Gratzl, Lesley H. Curtis, Ania Jastreboff, Yuan Lu, and Nicholas L. Stucky. “FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity.” JACC Adv 5, no. 2 (February 2026): 102575. https://doi.org/10.1016/j.jacadv.2025.102575.

Do D, Murugiah K, Sawano M, Goodwin Cartwright BM, Rodriguez PJ, Gratzl S, et al. FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity. JACC Adv. 2026 Feb;5(2):102575.

Do, Duy, et al. “FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity.” JACC Adv, vol. 5, no. 2, Feb. 2026, p. 102575. Pubmed, doi:10.1016/j.jacadv.2025.102575.

Do D, Murugiah K, Sawano M, Goodwin Cartwright BM, Rodriguez PJ, Gratzl S, Curtis LH, Jastreboff A, Lu Y, Stucky NL. FDA Cardiovascular Indication Expansion and Dispensing of Semaglutide/Tirzepatide in CVD Patients With Overweight/Obesity. JACC Adv. 2026 Feb;5(2):102575.